Dr. Peter Attia

Yeah.

Yeah.

And so what do you think would be the next mega unlock? Would it be on the data front? Would it be a predictive model? How could we shorten a clinical trial by 60%?

And so what do you think would be the next mega unlock? Would it be on the data front? Would it be a predictive model? How could we shorten a clinical trial by 60%?

You need a good biomarker.

You need a good biomarker.

Yeah. There undoubtedly are. There probably are.

Yeah. There undoubtedly are. There probably are.

Sue, what's your level of optimism or pessimism around liquid biopsies? And do you think that AI can help us with these?

Sue, what's your level of optimism or pessimism around liquid biopsies? And do you think that AI can help us with these?

And is this on the sensitivity front? Yeah.

And is this on the sensitivity front? Yeah.

Yeah, I was about to say, do you think the problem is tumors don't shed enough DNA?

Yeah, I was about to say, do you think the problem is tumors don't shed enough DNA?

I agree with you, by the way. I would add to that PSA in the hands of someone who understands what to do with it. So PSA by itself, pretty bad. PSA density when you know prostate volume and PSA velocity when you have serial measurements starts to become very predictive. So you take a man who has not had a prostate biopsy,

I agree with you, by the way. I would add to that PSA in the hands of someone who understands what to do with it. So PSA by itself, pretty bad. PSA density when you know prostate volume and PSA velocity when you have serial measurements starts to become very predictive. So you take a man who has not had a prostate biopsy,

and you stratify his PSA according to PSA density, the ability to predict if he has a Gleason 3 plus 3 or 3 plus 4 or 4 plus 3 is really quite high. It's high. And at least you can then stratify those patients more quickly into a PHI or a 4K and ultimately decide do they need a multi-parametric MRI and you go down that path.

and you stratify his PSA according to PSA density, the ability to predict if he has a Gleason 3 plus 3 or 3 plus 4 or 4 plus 3 is really quite high. It's high. And at least you can then stratify those patients more quickly into a PHI or a 4K and ultimately decide do they need a multi-parametric MRI and you go down that path.

So it's not turnkey and I completely understand why they've said we're going to make no recommendation. I do take comfort in knowing. It's sad to me, but I take comfort in knowing. Too many men are dying of prostate cancer. It should not be the third leading cause of cancer death. It shouldn't. And yet I understand that it's a big ask to get every doctor fully up to speed on the algorithm.

So it's not turnkey and I completely understand why they've said we're going to make no recommendation. I do take comfort in knowing. It's sad to me, but I take comfort in knowing. Too many men are dying of prostate cancer. It should not be the third leading cause of cancer death. It shouldn't. And yet I understand that it's a big ask to get every doctor fully up to speed on the algorithm.